NVAF Risk Assessment and Developing an Individualized Treatment Plan
hosted byPrime Education, LLCNVAF Risk Assessment and Developing an Individualized Treatment Plan is organized by Prime Education, LLC.
Release Date: August 25, 2023
Expiration Date: August 24, 2024
Description:
Despite robust evidence for the use of direct oral anticoagulants (DOACs) in the treatment of non-valvular atrial fibrillation (NVAF), many patients with NVAF receive only aspirin for cardiovascular disease prevention.
Test your clinical skills in patient risk assessment and individualizing treatment plans in this interactive clinical case challenge. See how you stack up against your peers as you consider treatment strategies and review expert narratives on the latest evidence in NVAF management.
Learning Objectives:
• Apply the 2021-2022 USPSTF recommendation on aspirin use for the prevention of cardiovascular disease to the management of patients with NVAF
• Assess the impact on cardiovascular outcomes associated with undertreatment and nontreatment of NVAF with oral anticoagulation
• Evaluate the latest clinical safety and efficacy data on oral anticoagulation and concomitant aspirin therapy for NVAF
• Align clinical practices with current evidence and guidelines for stroke prevention in patients with NVAF based on patient-specific factors
• Engage patients in shared decision-making discussions that involve individual patient's risk factors, treatment goals, and preferences
• Employ interprofessional practices for patient monitoring and care coordination among NVAF care teams to mitigate adverse bleeding events and support patient adherence
Agenda:
• CHA2DS2-VASc Risk Assessment
• Developing an Individualized Treatment Plan
• Guideline Recommendations for Aspirin
• Engaging Patient in Shared Decision-Making
• Initiation of DOAC Therapy
